Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
32.67
+0.09 (0.28%)
May 22, 2026, 4:00 PM EDT - Market closed
Cogent Biosciences Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Cogent Biosciences stock has a consensus rating of "Buy" and an average price target of $54.25. The average 1-year stock price forecast is 66.05% higher than the current stock price, while the lowest is $35 (+7.13%) and the highest is $72 (+120.39%).
Price Target: $54.25 (+66.05%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cogent Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 3 | 4 | 5 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $52 → $55 | Strong Buy | Maintains | $52 → $55 | +68.35% | May 6, 2026 |
| Wedbush | Wedbush | Buy Reiterates $55 | Buy | Reiterates | $55 | +68.35% | Mar 17, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $55 | Strong Buy | Initiates | $55 | +68.35% | Mar 16, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $39 → $52 | Buy | Maintains | $39 → $52 | +59.17% | Feb 18, 2026 |
| Wedbush | Wedbush | Buy Reiterates $55 | Buy | Reiterates | $55 | +68.35% | Jan 21, 2026 |
Financial Forecast
Revenue This Year
17.24M
Revenue Next Year
355.26M
from 17.24M
Increased by 1,961.03%
EPS This Year
-2.29
from -2.55
EPS Next Year
-0.83
from -2.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 44.0M | 830.2M | ||||||
| Avg | 17.2M | 355.3M | ||||||
| Low | n/a | 104.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 4,716.6% | ||||||
| Avg | - | 1,961.0% | ||||||
| Low | - | 508.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.73 | 1.35 | ||||||
| Avg | -2.29 | -0.83 | ||||||
| Low | -2.63 | -2.24 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.